BioSpace News Archive

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that new preclinical data characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and MDNA213, and a series of next generation IL-13 Superkine therapies, were presented at the 2023 Annual Meeting of the American Association for Cancer Research (AACR).

Bio-Techne (NASDAQ: TECH) and Lunaphore today announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers.

KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the presentation of new data on its lead pre-clinical candidate VET3-TGI presented in a poster session at the American Association for Cancer Research (AACR) in Orlando, Florida.

More Medicare beneficiaries than ever before who are living with diabetes and use insulin1 will now be eligible for reimbursement when using Abbott’s (NYSE: ABT) FreeStyle Libre® portfolio3,4 – the most prescribed and affordable continuous glucose monitoring system (CGM) in the United States.

BridGene Biosciences, Inc. announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.

Ra Medical Systems, Inc. (NYSE American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., participates in the European Heart Rhythm Association (EHRA). EHRA will take place in Barcelona, Spain from April 16-18.

Cognito Therapeutics , today announced executive leadership team appointments with Ralph Kern, M.D., as Chief Medical Officer and Kim Kwan as Chief Technology Officer who has been promoted from VP of Engineering.

Lundbeck to Present Broad Range of Data on Migraine and Brain Health at 75th Annual Meeting of the American Academy of Neurology.

Pieris Pharmaceuticals, Inc. announced the presentation of cinrebafusp alfa (PRS-343) clinical results from the Company’s study in 2L+ HER2-positive gastric cancer at the American Association for Cancer Research annual meeting.

IntelGenx Corp. today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s RIZAFILM ® VersaFilm ® 505(b)(2) new drug application (NDA) for the treatment of acute migraine.